862507-91-3

Upstream product

• 862507-35-5 6-chloro-N-(2,2-dimethylpropyl)-3-nitro-pyridin-2-amine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 5813-64-9 2.2-dimethylpropylamine 
• 862507-90-2 3-(2,2-dimethyl-propyl)-5-(4-fluoro-phenylethynyl)-3H-imidazo[4,5-b]pyridin-2-ylamine 

Downstream Products

• 862505-00-8 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine 

Relevant academic research and scientific papers

Combination therapy for ovarian cancer

The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.

COMBINATION THERAPY FOR OVARIAN CANCER

The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.

KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.